



April 30, 2018

Medline Industries, Inc.  
Pauline Maralit  
Regulatory Affairs Specialist  
Three Lakes Drive  
Northfield, IL 60093

Re: K180696

Trade/Device Name: Medline Green Ambidextrous Powder-Free Nitrile Examination Gloves with Colloidal Oatmeal (Tested for use with Chemotherapy Drugs)

Regulation Number: 21 CFR 880.6250

Regulation Name: Patient Examination Glove

Regulatory Class: I

Product Code: LZA, LZC

Dated: March 8, 2018

Received: March 16, 2018

Dear Pauline Maralit:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);

and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/>) and CDRH Learn (<http://www.fda.gov/Training/CDRHLearn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<http://www.fda.gov/DICE>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

  
Geeta K.  
Pamidimukkala -S

for Tina Kiang, Ph.D.  
Acting Director  
Division of Anesthesiology,  
General Hospital, Respiratory,  
Infection Control, and Dental Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known)  
K180696

Device Name

Medline Green Ambidextrous Powder-Free Nitrile Examination Gloves with Colloidal Oatmeal USP  
(Tested for use with Chemotherapy Drugs)

Indications for Use (Describe)

A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner.

These gloves were tested for use with chemotherapy drugs as per ASTM D6978-05 (Reapproved 2013) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.

Carmustine (BCNU) 3.3 mg/ml 13.2 minutes  
Cisplatin 1.0 mg/ml >240 minutes  
Cyclophosphamide (Cytosan) 20.0 mg/ml >240 minutes  
Dacarbazine (DTIC) 10.0 mg/ml >240 minutes  
Doxorubicin Hydrochloride 2.0 mg/ml >240 minutes  
Etoposide (Toposar) 20.0 mg/ml >240 minutes  
Fluorouracil 50.0 mg/ml >240 minutes  
Methotrexate 25.0 mg/ml >240 minutes  
Mitomycin C 0.5 mg/ml >240 minutes  
Paclitaxel (Taxol) 6.0 mg/ml >240 minutes  
Thiotepa 10.0 mg/ml 44.0 minutes  
Vincristine Sulfate 1.0 mg/ml >240 minutes

Please note that the following drug has extremely low permeation times:

Carmustine (BCNU) (3.3 mg/ml) 13.2 minutes

Please note that the following drug has low permeation times:

Thiotepa (10.0 mg/ml) 44.0 minutes

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
PRASStaff@fda.hhs.gov

*"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."*



Medline Industries, Inc.  
Three Lakes Drive  
Northfield, IL 60093

**K180696**

**Submitter / 510(k) Sponsor**

Medline Industries, Inc.  
Three Lakes Drive  
Northfield, IL 60093  
Registration Number: 1417592

**Contact Person**

Pauline Maralit  
Regulatory Affairs Specialist  
Phone: 847-949-2283  
Email: [pmaralit@medline.com](mailto:pmaralit@medline.com)

**Summary Preparation Date**

April 18, 2018

**Type of 510(k) Submission**

Traditional

**Device Name / Classification**

Name of Device: Patient Examination Glove (Tested for Use with Chemotherapy Drugs)  
Proprietary Name: Medline Green Ambidextrous Powder-Free Nitrile Examination Gloves with Colloidal Oatmeal USP (Tested for use with Chemotherapy Drugs)  
Common Name: Patient Examination Glove  
Classification Name: Patient Examination Glove  
Product Code: LZA, LZC  
Classification Panel: General Hospital  
Regulation #: 21 CFR 880.6250

**Predicate Device**

Medline Nitrile Powder-Free Examination Glove with Colloidal Oatmeal USP (Tested for Use with Chemotherapy Drugs) - K162982



Medline Industries, Inc.  
Three Lakes Drive  
Northfield, IL 60093

### Device Description

The Medline Green Ambidextrous Powder-Free Nitrile Examination Gloves with Colloidal Oatmeal USP (Tested for use with Chemotherapy Drugs) are non-sterile, single use, disposable gloves intended for medical purposes to be worn on the hands of examiners to prevent contamination between a patient and an examiner. The gloves are powder-free, ambidextrous with beaded cuff, green colored nitrile gloves featuring an inner coating of colloidal oatmeal USP. The gloves are offered in five sizes, extra-small, small, medium, large and extra-large.

The gloves are designed and manufactured in accordance with the ASTM D6319-10 standard and are tested for use with chemotherapy drugs per ASTM D6978-05 (Reapproved 2013).

### Indications for Use

A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner.

These gloves were tested for use with chemotherapy drugs as per ASTM D6978-05 (Reapproved 2013) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs.

**TABLE 1: Chemotherapy Drugs Tested**

<b>Chemotherapy Drug Tested</b>	<b>Breakthrough Time (in minutes)</b>
Carmustine (BCNU) 3.3 mg/ml	13.2
Cisplatin 1.0 mg/ml	>240
Cyclophosphamide (Cytoxan) 20.0 mg/ml	>240
Dacarbazine (DTIC) 10.0 mg/ml	>240
Doxorubicin Hydrochloride 2.0 mg/ml	>240
Etoposide (Toposar) 20.0 mg/ml	>240
Fluorouracil 50.0 mg/ml	>240
Methotrexate 25.0 mg/ml	>240
Mitomycin C 0.5 mg/ml	>240
Paclitaxel (Taxol) 6.0 mg/ml	>240
Thiotepa 10.0 mg/ml	44.0
Vincristine Sulfate 1.0 mg/ml	>240

Please note that the following drug has extremely low permeation times:  
Carmustine (BCNU) (3.3 mg/ml) 13.2 minutes.

Please note that the following drug has low permeation times:  
Thiotepa (10.0 mg/ml) 44.0 minutes.



Medline Industries, Inc.  
 Three Lakes Drive  
 Northfield, IL 60093

## Summary of Technological Characteristics

**TABLE 2: Comparison of Proposed and Predicate Devices**

Device Characteristic	Proposed Device	Predicate Device	Comparison Analysis
Product Name	Medline Green Ambidextrous Powder-Free Nitrile Examination Gloves with Colloidal Oatmeal USP (Tested for use with Chemotherapy Drugs)	Medline Nitrile Powder-Free Examination Glove with Colloidal Oatmeal USP (Tested for Use with Chemotherapy Drugs)	N/A
510(k) Reference	K180696	K162982	N/A
Product Owner	Medline Industries, Inc.	Medline Industries, Inc.	Same
Product Code	LZA, LZC	LZA, LZC	Same
Intended Use	A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner.  These gloves were tested for use with chemotherapy drugs as per ASTM D6978-05 (Reapproved 2013) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs	A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner.  These gloves were tested for use with chemotherapy drugs as per ASTM D6978-05 (Reapproved 2013) Standard Practice for Assessment of Medical Gloves to Permeation by Chemotherapy Drugs	Same
Regulation Number	21 CFR 880.6250	21 CFR 880.6250	Same
Materials	Nitrile, Colloidal Oatmeal	Nitrile, Colloidal Oatmeal	Same
Oatmeal Content	Min. 5mg for all sizes	Min. 5mg for all sizes	Same
Color	Green	White	Similar
Sizes	x- small, small, medium, large, x-large	x-small, small, medium, large, x-large	Same
Dimensions –	Complies with ASTM D6319-	Complies with ASTM D6319-	Same



Medline Industries, Inc.  
 Three Lakes Drive  
 Northfield, IL 60093

Length	10 220mm min.	10 230mm min.	
Dimensions - Width	Complies with ASTM D6319-10 X-small – 70±10mm Small – 80±10mm Medium – 95±10mm Large – 110±10mm X-large – 120±10mm	Complies with ASTM D6319-10 X-small – 70±10mm Small – 80±10mm Medium – 95±10mm Large – 110±10mm X-large – 120±10mm	Same
Dimensions - Thickness	Complies with ASTM D6319-10 Palm – 0.05mm min. Finger – 0.05mm min.	Complies with ASTM D6319-10 Palm – 0.05mm min. Finger – 0.05mm min.	Same
Physical Properties	Complies with ASTM D6319-10 minimum:  Tensile Strength: Before Aging ≥14 MPa, min. After Aging ≥14 MPa, min.	Complies with ASTM D6319-10 minimum:  Tensile Strength: Before Aging ≥14 MPa, min. After Aging ≥14 MPa, min.	Same
	Elongation: Before Aging 500%, min. After Aging 400%, min.	Elongation: Before Aging 500% min. After Aging 400% min.	
Freedom from Holes	Complies with ASTM D6319-10 and ASTM D5151-06 G-1, AQL 1.5	Complies with ASTM D6319-10 and ASTM D5151-06 G-1, AQL 1.5	Same
Powder or Powder-Free	Powder-Free	Powder-Free	Same
Residual Powder	Complies with ASTM D6319-10 <2mg per glove	Complies with ASTM D6319-10 <2mg per glove	Same
Contact Durations	Limited ≤24 hours	Limited ≤24 hours	Same
Biocompatibility	AAMI/ANSI/ISO 10993-10: Not a skin irritant Not a skin sensitizer	AAMI/ANSI/ISO 10993-10: Not a skin irritant Not a skin sensitizer	Same
Sterility	Non-sterile	Non-sterile	Same
Chemotherapy Drugs Tested with Minimum Breakthrough Detection Time as tested per ASTM D6978		Blenoxane 15 mg/ml >240 min.	Different
		Bortezomib 1 mg/ml >240 min.	Different
		Busulfan 6 mg/ml >240 min.	Different
	Carmustine (BCNU) 3.3 mg/m	Carmustine (BCNU) 3.3 mg/ml	Similar



Medline Industries, Inc.  
 Three Lakes Drive  
 Northfield, IL 60093

	13.2 min.	11.9 min.	
		Cetuximab (Erbix) 2 mg/ml >240 min.	<b>Different</b>
	Cisplatin 1.0 mg/ml >240 min.	Cisplatin 1.0 mg/ml >240 min.	<b>Same</b>
	Cyclophosphamide (Cytoxan) 20 mg/ml >240 min.	Cyclophosphamide (Cytoxan) 20.0 mg/ml >240 min.	<b>Same</b>
		Cytarabine 100 mg/ml >240 min.	<b>Different</b>
	Dacarbazine (DTIC)10.0 mg/ml >240 min.	Dacarbazine (DTIC)10.0 mg/ml >240 min.	<b>Same</b>
		Daunorubicin 5 mg/ml >240 min.	<b>Different</b>
		Docetaxel 10.0 mg/ml >240 min.	<b>Different</b>
	Doxorubicin Hydrochloride 2.0 mg/ml >240 min.	Doxorubicin Hydrochloride 2.0 mg/ml >240 min.	<b>Same</b>
		Ellence 2 mg/ml >240 min.	<b>Different</b>
	Etoposide (Toposar) 20.0 mg/ml >240 min.	Etoposide (Toposar) 20.0 mg/ml >240 min.	<b>Same</b>
		Fludarabine 25 mg/ml >240 min.	<b>Different</b>
	Fluorouracil 50.0 mg/ml >240 min.	Fluorouracil 50.0 mg/ml >240 min.	<b>Same</b>
		Gemcitabine (Gemzar) 38 mg/ml >240 min.	<b>Different</b>
		Idarubicin 1 mg/ml >240 min.	<b>Different</b>
		Ifosfamide 50.0 mg/ml >240 min.	<b>Different</b>
		Irinotecan 20.0 mg/ml >240 min.	<b>Different</b>
		Mechlorethamine HCl 1.0 mg/ml	<b>Different</b>





Medline Industries, Inc.  
 Three Lakes Drive  
 Northfield, IL 60093

	>240 min.	
	Melphalan 5 mg/ml >240 min.	<b>Different</b>
Methotrexate 25 mg/ml >240 min.	Methotrexate 25 mg/ml >240 min.	<b>Same</b>
	Methotrexate 50 mg/ml >240 min.	<b>Different</b>
Mitomycin C 0.5 mg/ml >240 min.	Mitomycin C 0.5 mg/ml >240 min.	<b>Same</b>
	Mitoxantrone 2.0 mg/ml >240 min.	<b>Different</b>
	Oxaliplatin 5 mg/ml >240 min.	<b>Different</b>
Paclitaxel (Taxol) 6.0 mg/ml >240 min.	Paclitaxel (Taxol) 6.0 mg/ml >240 min.	<b>Same</b>
	Paraplatin 10 mg/ml >240 min.	<b>Different</b>
	Pemetrexed Disodium 25 mg/ml >240 min.	<b>Different</b>
	Raltitrexed 0.5 mg/ml >240 min.	<b>Different</b>
	Rituximab 10 mg/ml >240 min.	<b>Different</b>
Thiotepa 10.0 mg/ml 44.0 min.	Thiotepa 10.0 mg/ml 18.6 min.	<b>Similar</b>
	Trisonex 0.1 mg/ml >240 min.	<b>Different</b>
	Vidaza (5-Azacytidine) 25 mg/ml >240 min.	<b>Different</b>
	Vinblastine 1 mg/ml >240 min.	<b>Different</b>
	Vinorelbine 10 mg/ml >240 min.	<b>Different</b>
Vincristine Sulfate 1.0 mg/ml >240 min.	Vincristine Sulfate 1.0 mg/ml >240 min.	<b>Same</b>



Medline Industries, Inc.  
Three Lakes Drive  
Northfield, IL 60093

## Summary of Non-Clinical Testing

The biocompatibility evaluation for Medline Green Ambidextrous Powder-Free Nitrile Examination Glove with Colloidal Oatmeal USP (Tested for Use with Chemotherapy Drugs) was conducted in accordance with ANSI/AAMI/ISO 10993-1:2009 *Biological Evaluation of Medical Devices—Part 1: Evaluation and Testing Within a Risk Management Process*, as recognized by FDA.

The following tests were performed to evaluate the biocompatibility of Medline Green Ambidextrous Powder-Free Nitrile Examination Glove with Colloidal Oatmeal USP (Tested for Use with Chemotherapy Drugs):

- ISO 10993-10: Primary Skin Irritation
- ISO 10993-10: Dermal Sensitization

In lieu of cytotoxicity and acute systemic toxicity testing for the Medline Green Ambidextrous Powder-Free Nitrile Examination Gloves with Colloidal Oatmeal USP (Tested for use with Chemotherapy Drugs), a Certificate of Analysis was provided for the color imparting compound to demonstrate it met its technical specifications and was safe for the intended use.

## Performance Testing (Bench)

Physical performance qualities of the proposed device were evaluated per ASTM D6319- 10, Standard Specification for Nitrile Examination Gloves for Medical Application.

Permeation testing was conducted to support the addition of the labeling claim: *Tested for use with chemotherapy drugs*. In addition, the proposed device was tested according to ASTM D6978- 05 (Reapproved 2013), Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs, in which minimum breakthrough times were determined for a wide range of chemotherapy drugs.

- ASTM D 6319-10 Standard Specification for Nitrile Examination Gloves for Medical Application
- ASTM D 6124-06 (Reaffirmation 2011) Standard Test Method for Residual Powder on Medical Gloves
- ASTM D 5151-06 (Reapproved 2011) Standard Test Method for Detection of Holes in Medical Gloves



**Medline Industries, Inc.**  
Three Lakes Drive  
Northfield, IL 60093

- ASTM D 6978-05 (Reapproved 2013) Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs

### **Conclusion**

In accordance with 21 CFR Part 807, and based on the information provided in this premarket notification, Medline Industries, Inc. concludes that Medline Green Ambidextrous Powder-Free Nitrile Examination Glove with Colloidal Oatmeal USP (Tested for Use with Chemotherapy Drugs) is as safe and effective for its intended use as the predicate device, the Medline Nitrile Powder-Free Examination Glove with Colloidal Oatmeal USP (Tested for Use with Chemotherapy Drugs), cleared under K162982.